Diligence Watchlist A live database of the situations we're tracking across public and private markets — ahead of client demand. Each entry sets out the company, why it's interesting, the questions we'd test, and the experts we'd put on it. Built for the hedge funds and private equity firms that move first.
Retatrutide is the most effective weight-loss drug the industry has produced. Lilly's Phase 3 data put weight loss at 28.3% at the highest dose over 80 weeks, with a subset crossing 30% — territory previously reserved for bariatric surgery. It is a triple agonist, hitting three hormone pathways where the current leader hits two and the original semaglutide hits one. It preserved more muscle than rival shots and improved knee osteoarthritis pain and sleep apnoea in trials. Lilly plans to file this year and reach market in 2027. The market is treating it as the next multi-billion-dollar franchise from the company that already sells the most lucrative drug in the world. The efficacy is not the question. The question is whether Lilly can convert it into the revenue the share price already assumes. Here's how we'd test it.
The situation
Lilly's obesity franchise is the engine under one of the most richly valued companies in healthcare. The model is straightforward: produce the most effective molecule, command a premium price, and ride a market growing at twenty per cent a year. Retatrutide is the next link in that chain — clinically, the strongest asset anyone has put into a pivotal trial. On the science, there is very little to argue about. The drug does what Lilly says it does, and it does more of it than anything else on the market.
The fragility is not in the molecule; it is in everything around it. By the time retatrutide launches, the obesity market will have stopped being a two-player premium duopoly and become a contested field on price. It arrives alongside tirzepatide, semaglutide, an approved oral GLP-1 pill, a competing combination from Novo, and a wave of next-generation molecules behind them. Payers are tightening, several states have dropped Medicaid coverage for obesity drugs, negotiated Medicare prices land in 2027, and list prices are already being cut by more than half through direct-to-consumer channels. The setup quietly assumes that the best drug commands the best economics. In a market shifting toward access and affordability, that is no longer a safe assumption.
The diligence thesis
The market is pricing retatrutide as if efficacy equals revenue. The contrarian read is that, in obesity in 2027, efficacy is necessary but no longer sufficient — and the variable that decides the outcome is monetisation: what the drug can be sold for, to whom, through which channel, and against how many alternatives, several of them Lilly's own. A fund underwriting the bull case is implicitly betting that the strongest molecule wins share at a price that protects the franchise. The bear case is that the obesity market is converging on a commodity-with-tiers structure, where the marginal patient is won on access and out-of-pocket cost, not the last two points of weight loss — and the premium retatrutide deserves on the data is not the premium it earns in the market.
There is a second, stranger condition that has to hold. Retatrutide is already one of the most-sold compounds you cannot legally buy. A large gray market in research-use-only peptides has been dosing it for two years, at a fraction of any future list price, building a following in fitness and biohacking circles before a single approved vial has shipped. Enforcement is now closing that market down — warning letters, raids, vendor shutdowns, failing purity tests. The bull case is that this funnels a primed, motivated audience toward the approved product as the cheap channel is shut and exposed as unsafe. The bear case is that the gray market has already taught a generation of users that this molecule is a commodity that costs tens of dollars, not hundreds, and that they will simply find the next unapproved supplier. The financials will eventually describe which happened. The behaviour that drives it is happening now, in places no filing reaches.
The primary research questions that matter
- Will the gray-market user convert to a paying patient? The people already using research-grade retatrutide are the most motivated early adopters in the market. We'd test, directly with that cohort, whether they intend to move to an approved prescription at list or near-list price — or whether two years of cheap supply has permanently anchored what they think the molecule is worth.
- Where does retatrutide sit in the prescriber's mind versus Lilly's own pill and tirzepatide? With an oral GLP-1 already launched and tirzepatide entrenched, we'd test how prescribers actually triage patients across Lilly's own portfolio — and whether retatrutide expands the franchise or cannibalises it.
- What will payers and PBMs actually cover, and at what tier? Formulary position decides volume. We'd test, with the people who build formularies, whether a higher-efficacy triple agonist earns preferred placement, or whether payers steer to cheaper GLP-1s and reserve retatrutide for the most severe patients.
- Does the side-effect profile cap real-world persistence? Discontinuation rates rose with dose in the trials. We'd test, with prescribers and patients, whether the gastrointestinal burden at effective doses limits how many patients stay on long enough to deliver the headline weight loss outside a trial setting.
- How fast does enforcement actually shut the gray channel — and where does that demand go? We'd test, with people who operate in and observe the peptide market, how quickly supply is genuinely drying up, whether demand is migrating to the approved product or to new unapproved sources, and how price expectations are moving as it happens.
Why this can't be answered from the filings
The trial data tells you the drug works; it tells you nothing about whether the gray-market user converts, what a PBM will pay, or how a prescriber chooses between three Lilly molecules. Those answers live with people the filings never quote: the clinicians writing obesity prescriptions today, the formulary and pharmacy-benefit decision-makers who set coverage, the telehealth operators watching demand and drop-off in real time, the patients deciding whether the result is worth the price and the nausea, and the operators who can see the gray peptide market contracting. Primary research is the method that reaches them — structured expert calls, prescriber and patient surveys, and channel checks across the prescribing and payer ecosystem that turn "will it monetise" into first-hand evidence of intent, coverage and willingness to pay. That is the difference between modelling a peak-sales number and pressure-testing it.
The experts we've recruited
- Obesity-medicine and endocrinology prescribers. Physicians who write GLP-1 and incretin prescriptions daily — able to speak to how they would position a triple agonist against existing options, including Lilly's own, and where it fits in real treatment pathways.
- Telehealth and weight-management platform operators. Commercial and clinical leaders at the consumer platforms that have driven much of GLP-1 demand — able to speak to conversion, persistence, price sensitivity and how patients actually behave when the bill arrives.
- Payer and pharmacy-benefit decision-makers. Practitioners who build formularies and negotiate drug coverage — able to speak to whether higher efficacy earns preferred tier placement or whether cost steering wins, and how 2027 pricing changes reshape access.
- Peptide-market and independent-testing operators. People who observe the research-use-only peptide ecosystem and the labs that test it — able to speak to how fast enforcement is shutting supply, the scale of counterfeit and purity problems, and where displaced demand is going.
- Former obesity-franchise commercial operators (departed). People who have run launch, pricing or market-access strategy for incretin drugs and have since left — able to speak to how a launch of this kind is actually priced and positioned, without holding any current inside information.
- Contract manufacturing and fill-finish supply executives. Independent operators across the injectable-peptide supply base — able to speak to whether the manufacturing and supply ramp can meet a launch of this scale, and how that constrains pricing strategy.
Commission this research
Woozle Research runs done-for-you primary research for hedge funds and private equity firms — expert calls, surveys and channel checks, delivered as finished intelligence rather than raw notes. For Lilly's retatrutide the experts are recruited and the questionnaire is ready; we move fast. Commission us to run this primary research for you — or build your own variant of the thesis — and request a quote.